Literature DB >> 11297540

MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation.

M W Jackson1, M S Lindstrom, S J Berberich.   

Abstract

Regulation of p53 involves a complex network of protein interactions. The primary regulator of p53 protein stability is the Mdm2 protein. ARF and MdmX are two proteins that have recently been shown to inhibit Mdm2-mediated degradation of p53 via distinct associations with Mdm2. We demonstrate here that ARF is capable of interacting with MdmX and in a manner similar to its association with Mdm2, sequestering MdmX within the nucleolus. The sequestration of MdmX by ARF results in an increase in p53 transactivation. In addition, the redistribution of MdmX by ARF requires that a nucleolar localization signal be present on MdmX. Although expression of either MdmX or ARF leads to Mdm2 stabilization, coexpression of both MdmX and ARF results in a decrease in Mdm2 protein levels. Similarly, increasing ARF protein levels in the presence of constant MdmX and Mdm2 leads to a dose-dependent decrease in Mdm2 levels. Under these conditions, ARF can synergistically reverse the ability of Mdm2 and MdmX to inhibit p53-dependent transactivation. Finally, the association and redistribution of MdmX by ARF has no effect on the protein stability of either ARF or MdmX. Taken together, these results demonstrate that the interaction between MdmX and ARF represents a novel pathway for regulating Mdm2 protein levels. Additionally, both MdmX and Mdm2, either individually or together, are capable of antagonizing the effects of the ARF tumor suppressor on p53 activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297540     DOI: 10.1074/jbc.M010685200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.

Authors:  Changgong Li; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

Review 2.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

3.  Regulation of p53-MDMX interaction by casein kinase 1 alpha.

Authors:  Lihong Chen; Changgong Li; Yu Pan; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

4.  RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Authors:  Yuan Xiao Zhu; Rodger Tiedemann; Chang-Xin Shi; Holly Yin; Jessica E Schmidt; Laura A Bruins; Jonathan J Keats; Esteban Braggio; Chris Sereduk; Spyro Mousses; A Keith Stewart
Journal:  Blood       Date:  2011-02-02       Impact factor: 22.113

Review 5.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

Review 6.  The regulation of the p53-mediated stress response by MDM2 and MDM4.

Authors:  Mary Ellen Perry
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

7.  14-3-3 sigma positively regulates p53 and suppresses tumor growth.

Authors:  Heng-Yin Yang; Yu-Ye Wen; Chih-Hsin Chen; Guillermina Lozano; Mong-Hong Lee
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  MDM2 promotes ubiquitination and degradation of MDMX.

Authors:  Yu Pan; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

9.  Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation.

Authors:  Sanjeev Shukla; Sanjay Gupta
Journal:  Free Radic Biol Med       Date:  2008-02-26       Impact factor: 7.376

10.  Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

Authors:  Christian A Merkel; Rafael B da Silva Soares; Anna Carolina V de Carvalho; Daniela B Zanatta; Marcio C Bajgelman; Paula Fratini; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.